SOURCE: Aoxing Pharmaceutical Co., Inc.

September 08, 2010 08:00 ET

Aoxing Pharmaceutical Company to Present at Rodman & Renshaw Annual Global Investor Conference 2010

NEW YORK, NY--(Marketwire - September 8, 2010) -  Aoxing Pharmaceutical Company, Inc. (NYSE Amex: AXN) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development, manufacturing and distribution of narcotic and pain-management products, today announced that the Company will be presenting at the Rodman & Renshaw Annual Global Investment Conference in New York City. Aoxing Pharma will be present at 2:00 PM EDT for the China Industry track on September 13, 2010 and at 4:05 EDT for the Healthcare Industry Track September 14, 2010.

Dr. David Shao, CFO will provide a review of recent pipeline developments, international collaborations and financial progress at Aoxing Pharma.

A live webcast and 90-day archive of the Company presentation will be available at:

About Aoxing Pharmaceutical Company, Inc.

Aoxing Pharmaceutical Company, Inc is a US incorporated specialty pharmaceutical company with its operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. Headquartered in Shijiazhuang City, outside Beijing, Aoxing has the largest and most advanced manufacturing facility in China for highly regulated narcotic medicines. Its facility is one of the few GMP facilities licensed for the manufacture of narcotic medicines by the China State Food and Drug Administration (SFDA). It has a joint venture collaboration with Johnson Matthey Plc to produce and market narcotics and neurological drugs in China. It also has strategic alliance partnership with QRxPharma, Phoenix PharmaLabs, Inc and American Oriental Bioengineering, Inc. For more information, please visit:

Safe Harbor Statement from Aoxing Pharmaceutical Company, Inc

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other risk factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-K for the year ended June 30, 2009, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

Contact Information

  • Investor Relations Contact:
    Brian Korb
    Vice President
    The Trout Group LLC
    Tel: +1 646 378 2923